New drug combo takes on deadly brain tumors
NCT ID NCT03423628
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests an experimental drug called AZD1390 combined with radiation therapy for people with glioblastoma or brain metastases. The main goal is to check safety and find the best dose. About 180 participants will receive different doses of AZD1390 alongside radiation to see how well the combination is tolerated.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD1390 (an experimental drug that blocks a protein called ATM, which may help radiation kill cancer cells more effectively)
What this could lead to
If it works, this could point toward a new way to treat aggressive brain tumors by making radiation more effective.
What could go wrong
This is a very early (Phase 1) study, so the main goal is safety, not effectiveness. The drug may not work or could cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGBoston, Massachusetts, 02114, United States
-
Research Site
RECRUITINGBoston, Massachusetts, 02215, United States
-
Research Site
RECRUITINGNew York, New York, 10065, United States
-
Research Site
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
-
Research Site
RECRUITINGRichmond, Virginia, 23298, United States
-
Research Site
COMPLETEDChūōku, 104-0045, Japan
-
Research Site
ACTIVE_NOT_RECRUITINGHidaka-shi, 350-1298, Japan
-
Research Site
ACTIVE_NOT_RECRUITINGKyoto, 606-8507, Japan
-
Research Site
ACTIVE_NOT_RECRUITINGCambridge, CB2 0QQ, United Kingdom
-
Research Site
COMPLETEDGlasgow, G12 0YN, United Kingdom
-
Research Site
RECRUITINGLeeds, LS9 7TF, United Kingdom
-
Research Site
WITHDRAWNLondon, W1T 7HA, United Kingdom